Publikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (13)

2024

  1. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

    Blood, Vol. 144, Núm. 11, pp. 1193-1205

  2. Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions

    Neuron, Vol. 112, Núm. 17, pp. 2886-2909.e16

2022

  1. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Institutional factors associated with adherence to enhanced recovery protocols for colorectal surgery: Secondary analysis of a multicenter study

    Journal of Clinical Anesthesia, Vol. 74

2020

  1. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

  2. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

  3. The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma

    Oncotarget, Vol. 11, Núm. 13, pp. 1172-1185

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

2015

  1. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

    JAMA - Journal of the American Medical Association, Vol. 313, Núm. 13, pp. 1347-1361

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2003

  1. Chemotherapy for Bladder Cancer [6] (multiple letters)

    New England Journal of Medicine

  2. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid

    Cancer, Vol. 97, Núm. 5, pp. 1186-1194